SIXA $33.07 -0.1248%
0296.HK $0.56 0%
GVCI $10.59 -0.1885%
SXLK.L $77.83 -0.2611%
8257.HK $0.12 7.4074%
JPIN $53.05 -0.5996%
FTCVU $10.05 0%
MDO.L $2.06 0%
IHTA $6.96 0.0431%
JOBY $4.65 -2.0042%
SRWG.L $1 207.80 -0.3136%
0QIH.L $0.09 0%
AC8.L $162.50 0%
OVBC $24.34 -2.5689%
WNDY.L $12.24 0.3772%
ARG.NZ $1.10 0.4566%
JFIN $5.52 2.9851%
OSTK $19.41 -3.9109%
0QW7.L $14.08 -0.9061%
AFT $12.46 0.2413%
MUDSW $0.00 0%
PBBK $11.50 -1.6253%
CU2G.L $41 737.50 0.2462%
POLR.L $471.00 0.1063%
ELE.MC $20.03 0.7292%
1912.HK $0.07 -1.5152%
RRBI $44.75 -1.165%
CRF $7.37 -0.5787%
MMU $10.06 0.3992%
0651.HK $0.13 0%
0757.HK $0.24 0%
ABMD $381.02 0%
FTFT $1.17 -0.7627%
VIV $8.37 -0.4167%
TZPS $10.15 0%
DCRCW $4.69 0%
6119.HK $0.40 1.2821%
DLN $60.89 -0.4904%
DECK $488.74 -0.3466%
HTUS $30.52 0.0262%
CLOEU $11.01 0%
ZEST $0.17 0%
HRL $40.19 -0.2606%
SPSY.L $170.70 -1.0435%
6190.HK $9.54 0%
PAB $42.52 0.5601%
SOFO $0.83 2.2167%
MLCEC.PA $0.83 0%
1388.HK $0.57 0%
AZBJ $25.59 -6.2145%
HYGB.L $82.93 1.1712%
IBKR $75.63 -0.3098%
TRAQ $10.50 0%
ARTEW $0.05 -19.7432%
JPN $28.58 0%
VIEIX $103.31 -0.6539%
ILF $25.43 0.276%
RCFA $10.51 0%
BREB.BR $100.20 -0.5952%
BK $40.02 -1.6224%
ALVAP.PA $9.36 -1.0571%
FRD $10.33 0.3116%
RDW.L $528.00 2.924%
RPTX $10.19 0.9911%
ERTH $47.17 0.6674%
MGLD $1.56 0%
CHMI-PB $20.78 1.3688%
FLXG.L $26.82 -6.69798%
SNBR $20.98 2.1422%
HCP $31.21 -3.0745%
GYLD $12.44 -0.3021%
STRO $5.47 0.0916%
ECOR3.SA $6.35 -4.0785%
WBIG $21.64 -0.4197%
1606.HK $1.09 0.9259%
GEHI $16.00 0%
MLSEQ.PA $0.01 0%
RHIM.L $2 168.00 -1.1851%
HOLUU $13.65 0%
ISMD $29.41 -0.5916%
NLOK $21.66 0%
0922.HK $0.15 1.3514%
ERIC $5.15 -0.0971%
0KCI.L $62.92 -0.2329%
RRH $20.91 -0.0516%
0QYU.L $82.19 -0.4476%
IDLV $28.23 -0.1592%
BKD $3.78 -1.948%
0526.HK $0.04 -2.3256%
BEC.SI $1.65 0%
BOD.L $0.95 0%
MODE.L $0.60 0%
ARGO $29.33 -0.0852%
BTEC.L $6.08 0.7871%
CAFO.PA $8.98 5.1522%
ECNS $31.44 -3.2615%
VTAQ $5.08 0%
0340.HK $0.38 -1.3158%
FSMD $31.19 -0.3196%
EMLD $10.27 0%
Eng
Логотип
Eng
Лого

Brii Biosciences Limited 2137.HK

$3.93

-$0.14 (-3.68%)
На 18:04, 12 мая 2023

Ключевые показатели

  • Marketcap

    2836091731.00000000

  • week52high

    15.28

  • week52low

    3.72

  • Revenue

    0

  • P/E TTM

    0

  • Beta

    0.00000000

  • EPS

    -2.48000000

  • Last Dividend

    0.00000000

  • Next Earnings Date

    24 мар 2023 г. в 12:00

Описание компании

Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.

Свежие комментарии

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%

  • Нет

    12%

Проголосовал 8 человек